RPL22 (F1J4Y) Rabbit mAb #54055
- WB
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 15 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ile70 of human RPL22 protein.
Background
RPL22 and RPL22L1 are highly related 60S ribosomal protein paralogs. They both function in protein synthesis and play distinct and sometimes antagonistic roles in hematopoietic stem cell development through p53 (1-3). RPL22 can directly regulate RPL22L1 expression by binding to an internal hairpin on the RPL22L1 mRNA. RPL22 has also been shown to interact with mRNAs for telomerase, histone H1, and EBER1, a noncoding RNA from the Epstein-Barr virus (EBV) (4-6). Both RPL22 and RPL22L1 have been shown to play roles in carcinogenesis. Inactivation of RPL22 can occur in acute lymphoblastic leukemias, which results in increased expression of Lin28B (2). Low expression of RPL22 has also been described in lung and gastric cancers (7,8). RPL22L1 has been implicated in prostate cancer, and its induction is associated with poor prognosis in colorectal cancer (9,10).
- Anderson, S.J. et al. (2007) Immunity 26, 759-72.
- Rao, S. et al. (2012) Blood 120, 3764-73.
- Zhang, Y. et al. (2013) Dev Cell 24, 411-25.
- Le, S. et al. (2000) Mol Biol Cell 11, 999-1010.
- Ni, J.Q. et al. (2006) Genes Dev 20, 1959-73.
- Toczyski, D.P. and Steitz, J.A. (1991) EMBO J 10, 459-66.
- Yang, M. et al. (2013) Med Oncol 30, 646.
- Sun, Z. et al. (2021) Med Sci Monit 27, e928375.
- Liang, Z. et al. (2019) Med Oncol 36, 56.
- Rao, S. et al. (2019) PLoS One 14, e0222392.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.